Researchers from The University of Texas MD Anderson Cancer Center are set to present promising results from several innovative clinical trials at the American Association for Cancer Research (AACR) Annual Meeting in 2025. Their findings offer new hope in the treatment of colorectal cancer, kidney cancer, and pancreatic cancer, featuring cutting-edge therapies like personalized vaccines, radiotherapy, and gene silencing techniques.
Personalized Vaccine Shows Promise for Colorectal Cancer Patients
At the AACR 2025 event, MD Anderson researchers will reveal the results of a clinical trial focused on a personalized vaccine for patients with metastatic colorectal cancer. Colorectal cancer patients often face limited treatment options, particularly when their tumors have a “cold” immune environment. Researchers led by Dr. Saurav Daniel Haldar and Dr. Michael Overman have developed a vaccine platform, NeoAg-VAX, that targets specific mutations in patients’ tumors.
The Phase I study, involving 28 patients, tested the vaccine alone and in combination with pembrolizumab immunotherapy. The vaccine proved safe, and most patients showed strong immune responses. These findings, to be presented on April 27, offer valuable insights into future cancer treatments that could better activate the body’s immune system against cancer.
Radiotherapy Offers Safer Alternative for Kidney Cancer
MD Anderson researchers will also discuss a clinical trial focusing on metastatic clear cell renal cell carcinoma (ccRCC), a form of kidney cancer. Traditional treatments for ccRCC, such as immunotherapy and tyrosine kinase inhibitors, often come with serious side effects. The research, led by Dr. Chad Tang and Dr. Pavlos Msaouel, tested metastasis-directed radiation therapy as a safer alternative.
The Phase II trial, which included 121 patients, showed that radiation therapy alone could control the cancer without the need for systemic treatments. Patients had a median progression-free survival of 18 months and a median survival free of systemic therapy of 34 months. The study also introduced a new blood test to predict patients’ responses, showing promising results. Dr. Tang will present these findings on April 28.
Exosomes Target Key Mutation in Pancreatic Cancer
Another groundbreaking study from MD Anderson examines the use of exosomes—tiny particles derived from bone marrow cells—as a delivery system for gene-silencing treatments in pancreatic cancer. Pancreatic cancer, often driven by the KRAS G12D mutation, has been notoriously difficult to treat. Researchers, including Dr. Valerie LeBleu and Dr. Shubham Pant, tested exosomes that carried small interfering RNA (siRNA) to silence the KRAS mutation.
The Phase I trial, which included 12 patients with metastatic pancreatic cancer, found that six patients experienced stable disease, with no dose-limiting toxicities. The results suggest that this innovative treatment, which targets the KRAS mutation directly, could become a key part of future pancreatic cancer therapies. The researchers also noted that combining this treatment with immune checkpoint blockers might enhance its effectiveness. Dr. LeBleu will present the results on April 29.
Exciting Advances in Cancer Treatment
In addition to the three major studies, MD Anderson will also present data on a new ATR kinase inhibitor, ART0380, in the treatment of advanced solid tumors. This targeted therapy, developed by MD Anderson’s Therapeutics Discovery division, has shown promising results in preclinical studies, and clinical trials are ongoing to evaluate its potential.
These presentations highlight the innovative and patient-focused approach that MD Anderson researchers are taking to develop new therapies for difficult-to-treat cancers. For more details on the upcoming AACR presentations, visit MDAnderson.org/AACR.
Related topics:
